CJC-1295 DAC COA: Analytical Verification & Purity Standards

CJC-1295 DAC COA Specifications and Analytical Summary

A CJC-1295 DAC COA (Certificate of Analysis) provides independent analytical confirmation of the peptide's identity, chemical purity, and bioburden profile. Verified through Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) and Electrospray Ionization Mass Spectrometry (ESI-MS), a compliant COA documents a minimum purity threshold of 98%, confirmed molecular mass (3647.28 g/mol), lot-specific batch tracking, and low endotoxin levels (<0.5 EU/mg) suitable for controlled in vitro and preclinical research applications.

Researchers analyzing a CJC-1295 with DAC lot must verify that analytical testing was performed by an independent, ISO 17025-accredited third-party laboratory. Comprehensive analytical documentation guarantees that the lyophilized peptide is free from truncated sequences, residual trifluoroacetic acid (TFA) salts, heavy metals, and bacterial endotoxins that could otherwise confound cell culture or animal study outcomes.

Molecular Structure and Pharmacokinetic Profile of CJC-1295 DAC

CJC-1295 with Drug Affinity Complex (DAC) is a synthetic 29-amino-acid analog of naturally occurring Growth Hormone-Releasing Hormone (GHRH). The base peptide sequence is modified at positions 2, 8, 15, and 27 to enhance enzymatic stability against dipeptidyl peptidase-IV (DPP-IV) degradation. The addition of the maleimido-propionic acid linker (the DAC moiety) at the C-terminus enables covalent binding to circulating serum albumin following administration in preclinical models.

Preclinical studies indicate that this irreversible albumin-binding mechanism drastically extends the biological half-life of the compound from minutes to several days. While unmodified GHRH fragments clear rapidly, CJC-1295 DAC sustains elevated growth hormone (GH) secretion and downstream insulin-like growth factor 1 (IGF-1) levels over extended observation periods. Researchers utilize this long-acting GHRH analog within our research peptide library to evaluate tissue repair, cellular regeneration, protein synthesis pathways, and somatotrophic signaling axis regulation.

Analytical Quality Criteria for Research Peptide COAs

High-throughput laboratory experimentation demands absolute lot-to-lot consistency. When reviewing analytical documentation, research institutions should cross-reference specific physical and chemical metrics against established quality control protocols. PX1 Research mandates that every batch undergo rigorous third-party verification prior to release.

Key quality parameters that must be clearly stated on a compliant CJC-1295 DAC Certificate of Analysis include:

1. HPLC Purity Determination: Chromatographic purity exceeding 98.0%, with individual peak integration showing minimal synthesis deletion sequences. 2. Mass Spectrometry (MS) Verification: Molecular mass matching the theoretical value of 3647.28 Da within a standard mass accuracy tolerance (±1 Da). 3. Endotoxin Quantification: Limulus Amebocyte Lysate (LAL) assay results confirming endotoxin concentration below 0.5 EU/mg. 4. Physical Appearance: Uniform white to off-white lyophilized cake or powder free of visible particulate matter. 5. Solubility & Reconstitution: Complete dissolution in sterile bacteriostatic water or dilute acetic acid without residual precipitation.

RP-HPLC Chromatographic Purity Analysis

Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) serves as the industry standard for quantifying peptide purity and detecting sequence-related impurities. During RP-HPLC, the CJC-1295 DAC sample is injected onto a C18 hydrophobic stationary phase column and eluted using a gradient of acetonitrile and water containing trifluoroacetic acid (TFA) as a counter-ion.

Ultraviolet (UV) absorbance detection, typically set at 214 nm or 220 nm to capture peptide bond absorption, generates a chromatogram displaying the main analyte peak alongside any potential trace impurities. A verifiable COA features a clean primary retention peak comprising over 98% of the total integrated peak area. Chromatograms showing broad peaks, split peaks, or significant baseline noise indicate improper synthesis, partial degradation, or residual organic solvents, rendering the batch unsuitable for high-precision assays.

Electrospray Ionization Mass Spectrometry (ESI-MS) Mass Confirmation

While RP-HPLC establishes chemical purity, Electrospray Ionization Mass Spectrometry (ESI-MS) is necessary to confirm molecular identity. ESI-MS ionizes the peptide sample into multiply charged species ([M+H]+, [M+2H]2+, [M+3H]3+), which are analyzed to determine the exact monoisotopic or average molecular weight.

The theoretical molecular weight of CJC-1295 DAC (C165H269N47O46) is approximately 3647.28 g/mol. Mass spectrometry data presented on a valid COA will illustrate a clear spectrum with deconvoluted mass peaks confirming this exact value. Mass variance outside acceptable parameters suggests sequence errors, missing amino acids (deletion peptides), or improper attachment of the maleimido-propionic acid DAC linker.

Bacterial Endotoxin Limits and Bioburden Testing

In cell culture and preclinical animal models, bacterial endotoxins—lipopolysaccharides (LPS) derived from the outer membrane of Gram-negative bacteria—can induce inflammatory responses, alter cellular gene expression, and distort experimental data. Therefore, non-quantitative purity metrics are insufficient for sensitive biological research.

Third-party laboratory testing utilizes kinetic chromogenic Limulus Amebocyte Lysate (LAL) assays to quantify endotoxin levels. PX1 Research enforces a strict threshold of <0.5 EU/mg for all research peptides. Verifying endotoxin compliance on the CJC-1295 DAC COA ensures that observed physiological responses in preclinical tissue repair assays stem entirely from GHRH receptor activation rather than immunogenic contamination.

Comparative Analysis: CJC-1295 DAC vs. Non-DAC and GHRH Class Analogs

Understanding the functional differences between long-acting and short-acting GHRH analogs is essential for experimental design. While CJC-1295 DAC incorporates the maleimido-propionic acid modification to prolong plasma availability via serum albumin binding, CJC-1295 without DAC (also known as Modified GRF 1-29) lacks this linker, resulting in a rapid pharmacokinetic half-life of approximately 30 minutes.

Researchers studying somatotroph stimulation pathways often compare or co-administer GHRH analogs with selective growth hormone secretagogue receptor (GHSR) agonists. For example, combining a GHRH analog with ipamorelin or ghrp-2 produces a synergistic elevation in GH release in animal models. Conversely, alternative GHRH derivatives such as sermorelin and tesamorelin offer distinct binding affinities and physiological half-lives. Reviewing the analytical documentation across these compounds allows investigators to select the precise kinetic profile required for their specific tissue repair or metabolic studies.

Laboratory Handling, Reconstitution, and Storage Protocols

Lyophilized CJC-1295 DAC is stable at room temperature for short periods during shipping, but long-term preservation requires controlled laboratory storage at -20°C or -80°C in a desiccated environment. Exposure to moisture, heat, and light accelerates peptide hydrolysis and oxidation.

For reconstitution in laboratory settings, researchers should follow standardized peptide reconstitution protocols. Use sterile bacteriostatic water (0.9% benzyl alcohol) or sterile normal saline, directing the solvent along the glass vial wall rather than directly onto the lyophilized cake. Gently swirl the vial until complete dissolution is achieved; avoid vigorous vortexing or mechanical agitation, which can induce shear stress and peptide aggregation. Reconstituted solutions should be aliquoted and stored at 4°C for short-term use (up to 30 days) or freeze-thawed minimally at -20°C for extended experimental timelines.

Institutional Sourcing, USA Manufacturing, and Traceability

Procuring research compounds for academic, clinical, or private research laboratories requires stringent supply chain control. Low-cost vendors often provide outdated, generic, or batch-unmatched COAs that fail to reflect the actual contents of the delivered vial. PX1 Research mitigates experimental risk by manufacturing peptides in USA-based, GMP-compliant facilities and issuing lot-specific documentation for every order.

Every batch undergoes comprehensive testing in an independent ISO 17025 accredited laboratory, ensuring 100% traceability from raw material synthesis to final lyophilization. Furthermore, research facilities utilizing wholesale lab accounts benefit from consistent batch reservation, dedicated analytical support, and immediate dispatch via same-day shipping (Monday through Friday) from our logistics centers in California and Arizona.